A recent study showed that influenza vaccination in the morning might be more effective.
British researchers evaluated 276 over 65 years between 2011 to 2013 were inoculated three different strains of influenza patients. These patients are at 9:00 ~ 11:00 and 15:00 ~ vaccinated between 5:00.
The researchers found that, within one month, in the morning to participate in the vaccinated group, there are two flu vaccine antibodies increase in the number of antibody after vaccination. However, a third strain of flu was no significant difference in the morning group and the afternoon group.
“We know that the immune response in a day, there will be fluctuations, we have to check whether this volatility will expand antibody response to the vaccine,” lead researcher Anna Phillips said. She comes from sports, exercise and rehabilitation School of the University of Birmingham.
“We found in the morning vaccine will be more effective, which not only helps vaccination policy may also provide clues for improving vaccination strategies,” Phillips said in a university news release.
According to the study’s co-author Janet Lord, “Every year, a large number of resources to try to prevent influenza infection, especially in the elderly, but only less than half of the antibody are adequately protected.”
Lord, a professor with the Institute on Aging University inflammation, he said: “Our findings suggest that, by the time of vaccination can be changed to improve the effect of the morning, and at no extra cost.
The researchers said they plan to conduct a large-scale study time influenza vaccines to test their hypothesis. They will also check if the pneumococcal vaccine in the morning if possible to improve the effectiveness of a vaccine to prevent pneumococcal pneumonia vaccine.
Related posts:
A new study finds that more than half of hospitals still don’t require their doctors, nurses and other health care providers to get vaccinated against the flu
The completion of the first Phase 2a clinical trial for SYN-004 is an important achievement for Synthetic Biologics
Study: Most Ebola Survivors Experience Brain Symptoms More Than Six Months After Initial Infection
Equality Survival Antiviral Therapy in Patients with HCV-related Cirrhosis of the General Population